Neuropace Inc. Form 8-K Summary
Business Context and Reporting Period
This Form 8-K reports on the results of the 2023 Annual Meeting of Stockholders held by Neuropace, Inc. on June 7, 2023. The meeting was conducted virtually via live webcast.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting results.
Material Changes and Voting Results
Two proposals were submitted to stockholders, both of which were approved:
- Proposal 1: Election of Directors
- Lisa Andrade: 8,506,611 votes For; 432,292 votes Withhold; 7,538,467 Broker Non-Votes.
- Joseph Lacob: 8,475,094 votes For; 463,809 votes Withhold; 7,538,467 Broker Non-Votes.
- Both nominees were elected to serve until the 2026 Annual Meeting.
- Proposal 2: Ratification of Independent Registered Public Accounting Firm
- PricewaterhouseCoopers LLP was ratified for the fiscal year ending December 31, 2023.
- Voting Results: 16,456,369 votes For; 9,012 votes Against; 11,989 votes Abstain; 0 Broker Non-Votes.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items.
Key Facts for Investor Verification
- Confirmation that Lisa Andrade and Joseph Lacob have officially assumed their roles as Class II directors.
- Verification that PricewaterhouseCoopers LLP is the appointed auditor for the fiscal year ending December 31, 2023.
- Review of the significant number of Broker Non-Votes (7,538,467) in the director election to understand potential proxy voting dynamics.